  The search for causative pharmacogenomic loci is being transformed by
integrative omics pipelines, but their outputs have only begun being applied to
test design. We assess the direction of the field in light of Biobanks/PheWAS,
omics atlases, and AI. We first assess the potential of recent epigenome and
spatial genome concepts, datasets, and methods to improve the functionality of
PIP-style pipelines. We then discuss new potential methods of genetic test
design on the basis of the outputs of such pipelines. We conclude with a vision
for a pharmacophenomic atlas, in which omics atlas data, PheWAS associations,
and biobank data would be used with AI to design thousands of genetic tests for
clinical deployment in an automated parallel process.
